U.S. markets open in 20 minutes
  • S&P Futures

    +19.50 (+0.46%)
  • Dow Futures

    +153.00 (+0.45%)
  • Nasdaq Futures

    +83.00 (+0.58%)
  • Russell 2000 Futures

    +9.90 (+0.43%)
  • Crude Oil

    -0.46 (-0.63%)
  • Gold

    +1.20 (+0.07%)
  • Silver

    +0.02 (+0.07%)

    +0.0023 (+0.19%)
  • 10-Yr Bond

    +0.0030 (+0.20%)
  • Vix

    -0.93 (-5.58%)

    -0.0041 (-0.30%)

    -0.2030 (-0.18%)

    -454.64 (-1.32%)
  • CMC Crypto 200

    +6.72 (+0.83%)
  • FTSE 100

    +29.14 (+0.41%)
  • Nikkei 225

    +0.34 (+0.00%)

These Stocks Are on The Brink of Breakouts

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

HENDERSON, NV / ACCESSWIRE / October 4, 2018 / Verastem, Inc., a biopharmaceutical company, with two potential therapies for leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. Recently made its investors a boatload signing some major deals. While it may be a little late on VSTM, there is another company working on a solution to the same cancers that has made impressive progress recently and could be the next major success story in the sector, Propanc Biopharma, Inc. (PPCB).

PPCB is an intriguing biotech firm, that erupted for over 7000% last month going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain as of the close on Wednesday. PPCB may start receiving increased attention from the street at any moment. PPCB has a 52 week high of $0.77. PPCB is currently readying for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with a serious patent portfolio. Those that find PPCB before its clinical trial could be in store for a great ride.

PPCB also discovered a key gene target for drug developers, Rac1B, which increased as a result of PRP treatment. This gene suppresses cellular motility and proliferation of CSCs by ultimately inhibiting TGF-β, a known growth factor responsible for tumorigenesis and metastasis.

PPCB's CEO James Nathanielsz said "We remain excited by these important discoveries, as suppressing the CSCs population whilst avoiding potential unwanted side effects towards normal stem cells means we have a targeted therapy that can control the spread of cancer. Metastasis, or spreading cancer, remains the main cause of patient death from cancer."

The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.

The company is also very close to its first-in-human studies. PPCB has some very exciting events on the horizon. Now is the perfect time to beat the crowd on PPCB.

A few companies to watch include: Propanc Biopharma, Inc. (PPCB), Verastem, Inc. (VSTM), New Age Beverages, Corp. (NBEV), Aphiria, Inc. (APHQF), and Oragenics, Inc. (NYSE American: OGEN).

Propanc Biopharma, Inc. (PPCB)

Market Cap: $11.09M Share Price: $0.068

Propanc Biopharma, Inc. (PPCB), recently announced the execution of a research collaboration agreement with the University of Jaén, Spain, for the provision of research services and scientific-technical advice for the Company's POP1 drug discovery program. The goal for the program is to synthesize and develop a backup clinical compound to the Company's lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors.

Verastem, Inc. (VSTM)

Market Cap: $226.24M Share Price: $4.66

Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, will present at the following upcoming investor conferences:

The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00pm EDT in New York City, NY, USA.

The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 8:00am EDT in New York City, NY, USA.

New Age Beverages Corp (NBEV)

Market Cap: $442.11M Share Price: $8.95

New Age Beverages Corp will be meeting with some of the major retailers in the country at NACS and will be taking orders on a first come, first serve basis, given anticipated demand. Zach Ross, Marketing Manager of the Brand Marley at New Age commented, "We believe we have developed unique consumer insights and accessed superior technology in CBD-infused beverages over the past year, and we are excited to share those insights with key retail partners. We believe we are in a position to bring national leadership to this emerging growth segment, and intend to launch the most efficacious and safe CBD-infused products for consumers, with the most responsible marketing and education to a segment that has potential to be transformative to healthy functional beverages."

Aphiria, Inc. (APHQF)

Market Cap: $3.28B Share Price: $13.28

Aphria Inc. just announced they will release their first quarter results for 2019 on October 12, 2018.

Oragenics, Inc. (OGEN)

Market Cap: $18.94M Share Price: $1.60

Oragenics, Inc. (OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM). The company presented at two conferences this week in New York City.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eighty-nine thousand four hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications, LLC